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Abstract 
Liver glycogen storage diseases (GSD) are disorders associated with severe dyslipidaemia which can induce cell membrane alterations. 
Reduced erythrocyte membrane fluidity has been associated with ischaemic ardiovascular disease. Our study has been designed to 
investigate membrane erythrocyte fluidity, and to determine its lipid composition and peroxidation parameters. Membrane rythrocyte 
fluidity has been studied by electron spin resonance (ESR) with two fatty acid nitroxide probes (5NS and 16NS). Twenty-five GSD cases 
aged 1-27 years and 15 controls aged 1-28 years were included. The erythrocyte membrane of GSD patients appeared less fluid with the 
two probes (P < 0.001). The membrane fatty acid pattern explained this reduced fluidity. Patients howed a relative saturated fatty acid 
(SFA) increase and polyunsaturated fatty acid (PUFA) decrease which induced lower PUFA/SFA ratio than in controls. We have 
provided evidence that the PUFA decrease was independent of the oxidative process. These findings should be taken into account for the 
management of the dietary treatment of GSD patients. 
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1. Introduction 
Glycogen storage diseases (GSD) are rare inherited 
metabolic disorders (1/25000 in Europe) with glycogen 
breakdown and glucose production impairment primarily 
in the liver and/or the muscles. The most severe hepatic 
forms are identified early in infancy. There are three types: 
GSD type Ia with glucose-6-phosphatase deficiency, GSD 
type Ib with glucose-6-phosphate translocase deficiency 
and GSD type III with amylo-l,6-glucosidase deficiency. 
Clinically, patients present a varying degree of fasting 
hypoglycaemia, hepatomegaly, growth delay and hyper- 
lipoproteinaemia such as hypertriglyceridaemia and/or hy- 
percholesterolaemia [1,2]. It has been demonstrated that 
lipid abnormalities are due to increased lipogenesis and 
decreased lipid catabolism [3,4], and that they are not 
completely amended by any appropriate dietary treatment 
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[5]. Hyperlipidaemia, increased plasma viscosity and ery- 
throcyte aggregation, and decreased erythrocyte deforma- 
bility have been identified as risk factors for ischaemic 
cardiovascular diseases [6-8]. Moreover, the effect of 
plasma lipoproteins on the lipid composition and the fluid- 
ity of erythrocyte membrane have been shown in various 
metabolic disorders or diets [9-11]. 
The aim of this study was to evaluate erythrocyte 
membrane abnormalities as an additional risk of athero- 
sclerosis. We have investigated the dynamics of erythro- 
cyte membrane lipids by physical techniques. We have 
also evaluated the lipid composition and peroxidation 
markers. The study included 25 cases (14 GSD type I and 
l lGSD type III) and 15 matched controls. 
2. Subjects and methods 
2.1. Subjects 
Twenty-five patients (14 females and 11 males) were 
included in the study. They were aged 1-27 years (mean 
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= 9). Fourteen subjects had GSD type I including 9 of 
type Ia and 5 of type lb. Eleven subjects had GSD type III. 
The patients were separated in two groups. Group G I 
included GSD type Ia and Ib with glycogenolysis and 
gluconeogenesis disturbances. Group G2 included GSD 
type III with glycogenolysis disorders and normal gluco- 
neogenesis, The diagnosis of GSD was ascertained on liver 
biopsies and/or erythrocytes and leucocytes, as published 
elsewhere [2]. Blood samples for routine tests were ob- 
tained from patients who had been fasting for 6 h because 
GSD type ! would have a severe risk of hypoglycaemia. A 
control group of 15 normolipaemic subjects (5 females and 
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Fig. 1. (a) Degree of order (S) as measured with 5NS probe, in controls 
and different groups of GSD (GI and G2). (b) The correlation-relaxation 
time (Tc) as measured with 16NS probe in controls and different groups 
of GSD (GI and G2). n sec indicates nano seconds• Values are mean+ 
S.D; a indicates comparison between controls and GSD (GI or G2); NS, 
not significant; * * * P < 0.001. 
similar fasting conditions to the GSD patients• Additional 
blood samples were collected in EDTA from patients and 
controls with the informed consent of the subjects' parents 
and/or the subjects themselves. 
2.2. Eo, throcyte membrane preparation 
Erythrocytes were washed three times with isotonic 
saline solution (150 mM NaC1, 5 mM sodium phosphate, 
pH 7.4). The buffy coat and the plasma were removed 
each time. The membranes were prepared by hypotonic 
haemolysis in 5 mM phosphate buffer (pH 8). They were 
isolated by centrifugation and washed three times with the 
same buffer [12]. The membrane protein content was esti- 
mated by the Lowry et al. method which utilizes bovine 
serum albumin as standard [13]. 
2.3. Spin labelling and electron spin resonance (ESR) 
study [14] 
Erythrocyte membranes were labelled either by the 5 
doxyl stearic acid (5NS) or the 16 doxyl stearic acid 
(16NS). The method consisted of a short incubation of 108 
cells in 1 /xl of the probe solution (final concentration 
2.10 -4 M) at room temperature. The sample was trans- 
ferred in capillary pipets into the resonator. The electron 
spin spectrometer was BRUCKER ECS 106 equipped with 
a 9202 tmh resonator. It was settled as follows: center field 
(3410 Gauss) swept with 100 Gauss; microwave fre- 
quency: 9.56 GHz; power: 20 mW. Three scans were 
recorded for each sample at room temperature (24°C + 
0.5°C). The degree of order was calculated from the 
coupling constants 2TII and 2T l [15], with the 5NS probe. 
The correlation-relaxation time was derived from the 
Keith's formula using the three main lines given by the 
16NS probe [16]. 
2.4. Membrane lipids and fatty acids measurements 
Lipids were extracted from erythrocyte membranes by 
chloroform/methanol (2:1, v/v).  The mixture was parted 
into two layers by centrifugation (1500 × g for 5 rain.). 
The chloroform layer represented the lower organic phase 
and the methanol/water layer was the upper phase. The 
extraction procedure was repeated twice [17]. Cholesterol 
and phospholipids containing choline (phosphatidylcholine 
and sphingomyelin) were measured by enzymatic methods 
with commercially available kits (bioM~rieux, Marcy 
l'Etoile, France) [18,19]. The fatty acids were transmeth- 
ylated at 55°C with 0.5 M methanolic potassium hydroxide 
and BF3/methanol [20]. The gas liquid chromatography 
(GLC) was carried out on a Delsi instrument (France) 
equipped with a 25-m glass capillary column containing 
PEG-20 M (Supelco, PA). The fatty acid methyl esters 
peaks were identified by their retention time [21 ] according 
to commercial standards (Nu-Chek-Prep, Elysian, MN). 
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2.5. Membrane peroxidation parameters measurements 
2.5.1. Membrane ce-tocopherol measurement 
c~-Tocopherol was measured in erythrocyte membranes 
by high-performance liquid chromatography (HPLC) [22]. 
Separation was achieved using an RP18 Ultrapack (25 × 
4.6 mm; 5 /xm) analytical column (SFCC/Shandon, 
France). Methanol was used as mobile phase and c~- 
tocopherol acetate as internal standard. The spectrophoto- 
metric detection was achieved at 292 nm (Waters spectro- 
photometer LC 455). 
2.5.2. Membrane thiobarbituric acid-reactive substances 
(TBARS) measurement 
The TBARS concentration i erythrocyte membranes 
was measured by the method of Conti et al. [23] modified 
by Keddad et al. [24]. The detection was conducted with 
synchronous fluorescence (Shimadzu RF 540 coupled to a 
Shimadzu DR 3 data recorder module). TBARS fluores- 
cence spectra were recorded between 500 and 600 nm by 
simultaneous variation of emission and excitation wave- 
lengths with a constant A interval of 14 nm. 
2.6. Statistical analysis 
Data are expressed as mean ___ S.D. Comparison be- 
tween controls and patients were performed by ANOVA 
and Mann-Whitney's U-test [25]. 
3. Results 
Fig. la,b displays the results obtained by the electron 
spin resonance (ESR) study for probes 5NS and 16NS 
Table l 
Comparison of erythrocyte membrane lipids in controls and GI ,  G2 
patients groups 
Parameters Controls (n = 15) Patients 
GI (n= 14) G2(n= 11) 
CL, ( k~mol/g 0.37 ± 0.09 0.31 ± 0.08 0.35 ± 0.1 
proteins) 
PL, ( / zmol /g  0.27 ± 0.07 0,31 ± 0.09 0.32 ± 0.01 
proteins) 
CL /PL  1.40±0.09 1.01_+0.18 . . . . .  1.13±0.27 . . . .  
CL indicates cholesterol; PL, phospholipids containing choline (choline- 
phospholipids and sphingomyelin). Values are mean±S.D.  ~ Indicates 
comparison between controls and G1 patients group or G2 patients group. 
**~ P < 0.00l. 
respectively. The degree of order (S) obtained with 5NS 
was markedly increased for patients of group G1 (0.758 _ 
0.017) and group G2 (0.763 _+ 0.012). These data were 
significantly different from the control group (0.725 + 
0.004), P < 0.001. There was no difference between group 
G1 and G2. The correlation-relaxation time (~-c) values 
found with probe 16NS were increased for patients of 
group G1 (3.79 + 1.33) and group G2 (2.94 + 0.49). The 
~-c values for the control group were consistent with 
previous studies [26]. There was no significant difference 
between group G1 and G2. However, ~-c values were 
lower in group G2 than G1. With respect o 'fluidity', the 
erythrocyte membrane of GSD patients appeared ramati- 
cally less fluid when compared to healthy subjects. 
In Table 1, the three groups showed the same amount of 
cholesterol and phospholipids containing choline. GSD 
patients had lower cholesterol/phospholipids containing 
choline ratio (CL/PL), (P < 0.001). 
Table 2 presents the overall fatty acid composition of 
Table 2 
Erythrocyte membrane fatty acid composition in controls and G1, G2 patients groups expressed in mmol /g  proteins 
Parameters Controls (n = 15) Patients (mmol /g  proteins) Controls Patients (%) 
(mmol /g  proteins) G1 (n = 14) G2 (n = 11) (n = 15)(%) G1 (n = 14) 
and in % 
G2(n= 11) 
16:0(PA) 0 .18±0.02  0 .28±0.08  ~'*** 0 .32±0.07  a,*** 20.49+ 1.09 23 .13±3.77  a,. 26 .12±3.33  ~'***'b'* 
16:1n-9 0 .004±0.001 0 .034±0.02  "* * * 0 .032±0.019 ~'* * * 0.27 ± 0.10 0 .83+0,39  ~'* * 0 .98±0.55  a,* • 
18:0(SA) 0 .16±0.02  0.22_+0.04a'** • 0.19_+0.03 a,*,b,* 18.63_+0.72 17.94+ 1,49 15.88_+ 1.05 ~'~**'b . . . .  
18: ln-9(OA) 0 .11±0.02  0 .16±0.04" ' * ' *  0,16_+0.03 a. . . .  12.72± 1,68 13.23___ 1,59 13.10± 1.08 
18:2n-6 (LA) 0 .11±0.02  0 .15+0.04  ~' '*  0 ,15+0.04  a'** 13.12_+1,90 12.40±2.51 12.32 ± 2.07 
20:3n-6 (DHLA) 0 .019±0.005 0.035 -t-0.009 ~'* * * 0,025_+0.007 ~'* *,m* * 2 .16±0,55  2.92_+0.51 ~'~ * * 2.21 +0.49  b . . . .  
20:4n-6 (AA) 0 .16±0.02  0.20_+0.04 ""  * * 0.20_+0.03 . . . .  18.88±0.91 17.09±2.19 a'* * 16.66_+ 1.67 a.* * 
22:4n-6 0.032 ± 0.006 0.043 _+ 0.012 a' * * 0.036 ± 0.011 3.57 ± 0.37 3.58 ± 0.91 3.07 ± 0.65 
22:5n-6 0.008 ± 0.002 0.014 ± 0.006 ~' * * 0.012 ± 0.005 "' ~ 0.85 ± 0.33 1.10 ± 0.32 1.03 _+ 0.38 
22:5n-3 0.021 ± 0.003 0.024 ± 0.007 0.022 ± 0.004 2.40 ± 0.30 2.04 ± 0.431 ~' * ~ 1.82 _+ 0.32 "' * * 
22:6n-3 (DHA) 0.053 ± 0.001 0.064 ± 0.025 0.070 ± 0.012 6.19 + 1.38 5.35 ± 2.11 5.56 ± 1.11 
PUFA 0.41 ±0.04  0.54_+0.11~'*** 0.52_+0.08 ~'*** 47.66_+3.62 44 .75±3.39  ~'* 43 .32±3.15  a,** 
SFA 0 .34±0.05  0 .50±0.11~'***  0.51 ±0.09  ~'** ~ 39 .32± 1.57 41.58 _+ 2.86 "' * 42.33_+2.66 ~'* 
PUFA/SFA 1 .21±0.14  1.11 ±0.15  a'* 1.03 ± 0.14 a'** 1 .22+0.14 1.09 ± 0.15 a'* 1.03___0.14 a'** 
TFA 0 .88±0.11  1 .20±0.24  a'* * * 1 .15+0.19 ". . . .  
PA, palm±tic acid; SA, stearic acid; OA, oleic acid; LA, linoleic acid; DHLA, dihomogammalinolenic acid; AA, arachidonic acid; DHA, docosahexanoic 
acid; PUFA, polyunsaturated fatty acids; SFA, saturated fatty acids; TFA, total fatty acids. Values are mean ± S.D. a indicates comparison between 
controls and GI patients group or G2 patients group; ~ indicates comparison between GI and G2. * P < 0.05, * * P < 0.01, * ~ ~ P < 0.001. 
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Table 3 
Comparison of erythrocyte membrane peroxidation parameters in controls 
and G l, G2 patients groups 
Parameters Controls (n  = 15) Patients 
GI (n= 14) G2(n=l l )  
~-toco, ( /zmol /g  1.08±0.18 1.05--+0.46 1.02±0.31 
proteins) 
o~-toco/PUFA 2.63-+0.48 2.04-+ 1.02 a.~ 1.95±0.52 a'~ 
TBARS, ( /xmol /g  0.61 ±0.35 0.71 -+0.41 0.65-+0.40 
proteins) 
TBARS/PUFA 1.49 -+ 0.90 1.27 -+ 0.66 1.33 ± 0.98 
o~-toco, cr-tocopherol; PUFA, polyunsaturated fatty acids; TBARS, thio- 
barbituric acid-reactive substances. Values are mean+S.D. ~ Indicates 
comparison between controls and GI patients group or G2 patients group. 
* P < 0.05. 
erythrocyte membrane. Fatty acid amounts were signifi- 
cantly higher for group G1 than in control group. Group 
G2 showed roughly the same pattem. Group GI and G2 
had an increase in polyunsaturated fatty acids (PUFA) and 
saturated fatty acids (SFA). PUFA/SFA ratio, another 
fluidity modulator [27] was significantly lower in group 
G1 and G2 than in the control group. Expressed as per- 
centage of the total fatty acids, patients exhibited an 
increase in palmitic acid and particularly in the G2 group. 
In this group the stearic acid (C18:0) was significantly 
lower compared both with the G1 group and the control 
one. In contrast, the percentage of arachidonic acid was 
lowered in all patients with respect o controls. The lower 
PUFA and the higher SFA percentages observed in pa- 
tients were significantly different compared to the control 
group. There was no significant difference in these per- 
centages between group GI and G2. 
Table 3 shows peroxidation parameters data. c~- 
Tocopherol is the major antioxidant in biological mem- 
branes. The thiobarbituric acid-reactive substances 
(TBARS) are end products of lipid peroxidation. There 
was no significant difference between patients and controls 
concerning c~-tocopherol, TBARS. Nevertheless, the c~- 
tocopherol/PUFA ratio was slightly decreased (P  < 0.05). 
4. Discussion 
We report the first study on membrane fluidity, lipid 
composition and peroxidation parameters in GSD. 
We have used ESR spectroscopy with two probes on 
two different erythrocyte membrane locations. The probe 
5NS was on the external hemileaflet to estimate the degree 
of molecular order (S). The corresponding probe 16NS 
was near the interface between the two membrane hemi- 
layers to measure the correlation-relaxation time (~-c). The 
~-c was directly related to the whole membrane fluidity. 
The S and ~-c values were dramatically increased in 
GSD patients compared to controls. However, there was 
no significant difference between groups G1 and G2 (Fig. 
l a,b). The role of several parameters might explain such 
an increase of both membrane degree of order, and viscos- 
ity. The CL/PL  ratio is one of the main modulators of 
membrane fluidity [11]. Surprisingly the ratio was lower 
for GSD patients (Table 1). Cholesterol is an exchangeable 
molecule [11]. It might have been partially removed uring 
exchanges with triglyceride-rich lipoproteins. These lipo- 
proteins are particularly numerous in GSD patients [5]. Our 
phospholipid assays referred only to phosphatidylcholine 
and sphingomyelin which are mainly located in the outer 
hemileaflet in human erythrocytes. Cholesterol and phos- 
pholipid values were similar for GSD and controls. Hence, 
the apparent viscosity and the S increase were presumably 
dependent on others modulators. 
The fatty acid content of phospholipids in the mem- 
brane also plays an important role in the fluidity and order 
variation. This is particularly true for phosphatidylcholine 
and sphingomyelin which contain noticeable amounts of 
saturated fatty acids [28,29] especially palmitic acid. The 
fatty acid pattern obtained in GSD patients displayed two 
major trends: an overall decrease in the polyunsaturated 
fatty acids (PUFA) and an associated increase in saturated 
fatty acids (SFA). Only one study has been published on 
the fatty acid content of erythrocyte lipids and concern 
GSD type 1 only [30]. The authors reported that these 
patients had increased PUFA level at the expense of SFA 
when compared to controls [30]. This finding is not consis- 
tent with our results and could be explained by the differ- 
ent normal values found in the control group. Agostoni et 
al. have noted higher SFA (55% vs 39%) and lower PUFA 
(26% vs 47%) [30]. Our reference values are closely 
related to those found in other studies [28,31] and docu- 
mented the relative SFA increase and PUFA decrease in 
plasma [32,33]. We can use the PUFA/SFA ratio as a 
fluidity modulator [27]. This ratio was decreased in pa- 
tients particularly in group G2. This finding was consistent 
with the decrease in membrane fluidity observed. Further- 
more, the synergistic effect of the opposite variations in 
PUFA and SFA is important for the membrane physico- 
chemical modifications observed. The apparent decrease of 
the PUFA percentage might be the result of several causes. 
An important one is the peroxidative process which is 
known to induce membrane alterations [34]. The normal 
values of TBARS and the slight decrease of ce- 
tocopherol/PUFA ratio were recorded but we cannot con- 
clude upon a role of the peroxidation in the viscosity 
observed in the GSD group. 
In conclusion, our study reports that erythrocyte mem- 
branes in GSD patients were less fluid than in controls. 
Based on our lipid investigations, it seems that membrane 
fluidity is modulated by compositional changes of fatty 
acids in membrane phospholipids, irrespective of lipid 
peroxidation. Further studies on associated physico-chem- 
ical changes in other cell membranes and lipoprotein struc- 
ture are needed to conclude on a general trend towards 
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order and viscosity in GSD. They are currently under 
development. However, our findings should take place in 
the long-term risk of ischaemic ardiovascular disease for 
GSD patients. Their nutritional treatment, including an 
increased mono-unsaturated and polyunsaturated fatty acid 
intake, could be an efficient strategy to maintain a better 
membrane fluidity. 
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